Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status

The phase III REMoxTB study prospectively enrolled HIV-positive (with CD4+ count> 250 cells, not on anti-retroviral therapy) and HIV-negative patients. We investigated the incidence of adverse events and cure...

Source: BMC Pulmonary Medicine - August 14, 2019 Category: Respiratory Medicine Authors: Conor D. Tweed, Angela M. Crook, Rodney Dawson, Andreas H. Diacon, Timothy D. McHugh, Carl M. Mendel, Sarah K. Meredith, Lerato Mohapi, Michael E. Murphy, Andrew J. Nunn, Patrick P. J. Phillips, Kasha P. Singh, Melvin Spigelman and Stephen H. Gillespie Tags: Research article Source Type: research